The 2 analysts offering 12-month price forecasts for Ovid Therapeutics Inc have a median target of 4.50, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +149.31% increase from the last price of 1.81.
The current consensus among 4 polled investment analysts is to Buy stock in Ovid Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.18
Reporting Date Mar 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.